In Brief: Spine-Tech
This article was originally published in The Gray Sheet
Executive Summary
Spine-Tech: Firm plans controlled worldwide market launch in the fourth quarter of 1997 of its BAK/Proximity implant for use in spinal fusion procedures to treat symptomatic degenerative disc disease following recent marketing clearance from FDA, the firm states. The device, which is intended for use in patients with a small anatomy, differs from the firm's flagship BAK implant in that it features "greater porosity," concave sides, and allows for closer placement between the vertebrae of two implants, one BAK and one BAK/Proximity...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.